Eyes on bookrunner roles on CJ Healthcare IPO The biotech firm’s owner has a strong tie with KB Securities and Samsung Securities
Translated by Ryu Ho-joung 공개 2019-12-05 08:00:00
이 기사는 2019년 12월 05일 08:00 thebell 에 표출된 기사입니다.
South Korea’s CJ Healthcare and its owner Kolmar Korea are expected to name bookrunners on its planned initial public offering (IPO) soon. All eyes are on who wins a senior role on the offering, with some industry watchers observing that some of the firms in the short list might have the upper hand in the competition.CJ Healthcare, a biotech company the Kolmar Korea-led consortium bought from CJ Group in 2018, is set to select underwriters for its planed listing as soon as early December. Included in the short list are five domestic brokerage firms – Mirae Asset Daewoo, Korea Investment & Securities, Samsung Securities, KB Securities and Shinhan Investment – as well as the U.S. investment bank JP Morgan.
The IPO plan has been revived this year by the new owner. During its first attempt at a listing, the company was originally working with NH Investment & Securities. The brokerage house, however, unexpectedly failed to be included in the short list, making the result more unpredictable.
Industry watchers say KB Securities and Samsung Securities, among other underwriters, should be “top-tier,” as both of them have a strong relationship with the company’s new owner Kolmar Korea.
In particular, KB Securities provided acquisition financing to Kolmar Korea when the maker of cosmetics and healthcare goods purchased CJ Healthcare last April. It also acted as lead manager on CJ Healthcare’s first bond offering. Meanwhile, Samsung Securities reportedly has a strong connection with Kolmar Korea’s top officials, including the chief executive.
Korea Investment & Securities and Mirae Asset Daewoo are also considered a viable choice, with their strong track record in the biotech sector. “There is nothing concrete yet about the number or composition of potential bookrunners,” a market insider said. “When only considering networking between the issuer and underwriters, it would be accurate to say that KB Securities and Samsung Securities have stronger ties [with the issuer] than any other candidates.”
It is thought to be a sure thing that JP Morgan, the only candidate in the short list among overseas firms, will work on the biotech company’s IPO due to strong support from three financial investors – H&Q, Mirae Asset Private Equity and STIC Investment – who participated in a consortium led by Kolmar Korea to invest in CJ Healthcare.
These private equity firms hold a 49.3 percent stake in aggregate. Kolmar Korea promised them it would help their exit by taking the company public by 2022. They reportedly demanded to include an overseas underwriter, aiming at attracting demand from global institutional investors.
The fact that Ha Jin-soo, who used to work with CJ Healthcare during its first IPO attempt when he was with NH Investment, is currently leading JP Morgan’s Korea ECM division also raises the possibility of the investment bank securing a bookrunner role on the deal.
“It is highly likely that the issuer will include an overseas investment bank among bookrunners considering a nearly-half stake held by three financial investors. [These investors] strongly support JP Morgan,” said a source in the investment banking industry. “Mr. Ha is playing a pivotal role in the process,” he added.
(By reporter Kim Si-mok)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감